Login to Your Account



FDA puts partial hold on CTI's pacritinib studies

By Michael Fitzhugh
Staff Writer

Monday, February 8, 2016

The FDA placed a partial clinical hold on trials of CTI Biopharma Corp.'s lead candidate, pacritinib, citing fatal and life-threatening safety issues in patients treated with the drug vs. those provided best available therapy other than JAK inhibitors in the control arm of PERSIST-1, a phase III study of primary myelofibrosis (MF).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription